Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments
暂无分享,去创建一个
[1] F. Turnbull. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.
[2] François Gueyffier,et al. J-Shaped Relationship between Blood Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of Individual-Patient Data , 2002, Annals of Internal Medicine.
[3] Salim Yusuf,et al. Blood-pressure reduction and cardiovascular risk in HOPE study , 2001, The Lancet.
[4] Jan A Staessen,et al. Cardiovascular protection and blood pressure reduction: a meta-analysis , 2001, The Lancet.
[5] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[6] Barry R. Davis,et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.
[7] T. Hedner,et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.
[8] S J Pocock,et al. Assessing treatment-time interaction in clinical trials with time to event data: a meta-analysis of hypertension trials. , 1998, Statistics in medicine.
[9] G. Molenberghs,et al. Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.
[10] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[11] P. Hartigan,et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.
[12] S. Pocock,et al. INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results. , 1995, Therapie.
[13] B. Dahlöf,et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) , 1991, The Lancet.
[14] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.
[15] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.
[16] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[17] T S Warrender,et al. Randomised trial of treatment of hypertension in elderly patients in primary care. , 1986, British medical journal.
[18] MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. , 1985, British medical journal.
[19] C. Bulpitt,et al. Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial , 1985, The Lancet.
[20] J. Abernethy. The Australian therapeutic trial in mild hypertension. , 1984, Hypertension.
[21] A. Doyle,et al. The Australian Therapeutic Trial in Mild Hypertension. , 1982, Nephron.
[22] E. Frohlich,et al. EVALUATION OF DRUG TREATMENT IN MILD HYPERTENSION: VA‐NHLBI FEASIBILITY TRIAL * , 1978, Annals of the New York Academy of Sciences.
[23] M. Kenward,et al. An Introduction to the Bootstrap , 2007 .
[24] D. Ruppert,et al. Measurement Error in Nonlinear Models , 1995 .
[25] B. Graubard,et al. Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.
[26] C. Dollery,et al. Medical Research Council trial of treatment of hypertension in older adults: principal results. , 1992 .
[28] L H Kuller,et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. , 1989, Stroke.
[29] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .